Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study

  • A. Chiricozzi (Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) (Creator)
  • S. M. Ferrucci (Creator)
  • Nardo L. Di (Creator)
  • N. Gori (Creator)
  • A. Balato (Creator)
  • M. Ortoncelli (Creator)
  • M. Maurelli (Creator)
  • M. Galluzzo (Creator)
  • Campos M. Munera (Contributor)
  • T. Seremet (Creator)
  • Giacomo Caldarola (Creator)
  • Clara De Simone (Creator)
  • E. Ippoliti (Creator)
  • T. Torres (Creator)
  • S. Gkalpakiotis (Creator)
  • C. Conrad (Creator)
  • J.M. Carrascosa (Creator)
  • L Bianchi (Creator)
  • G Argenziano (Creator)
  • S. Ribero (Creator)
  • G. Girolomoni (Creator)
  • A V Marzano (Creator)
  • Ketty Peris (Creator)

Dataset

Description

Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce. A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts. A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (
Dati resi disponibili2023
EditoreTaylor & Francis

Cita questo